Halt cardiomyOPathy progrEssion in Duchenne (HOPE-OLE)

Duchenne Muscular Dystrophy Clinical Trial

— HOPE-OLE  

Official title:

Open-Label Extension of the Halt Cardiomyopathy Progression in Duchenne (HOPE-Duchenne) Trial (CAP-1002-DMD-03)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06304064
• Other study ID #: CAP-1002-DMD-03
• Status: Completed
• Phase: Phase 2
• Start date: June 21, 2018
• Est. completion date: March 6, 2019

Study information

• Verified date: March 2024
• Source: Capricor Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This Phase 2, multi-center, open-label extension trial will provide CAP-1002 to participants who were randomized to the Usual Care treatment group of the HOPE-Duchenne study (NCT02485938) and completed 12 months of follow-up. The trial will assess the safety and efficacy of two intravenous administrations of CAP-1002, each separated by three months.

Description:

Participants with documented enrollment in the Usual Care treatment group of the HOPE-Duchenne study and completion of study follow-up through Month 12 were eligible for this study. Participants will undergo a targeted screening during a 30-day screening period, eligible subjects will then undergo baseline safety and efficacy assessments on Day 1 prior to their first infusion of CAP-1002. All CAP-1002 infusions will be conducted in an outpatient setting at the investigative site on Day 1 and at Month 3. Participants will be observed in the outpatient setting for at least two hours post-infusion and then discharged the same day if medically cleared by the site Investigator.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 8
• Est. completion date: March 6, 2019
• Est. primary completion date: March 6, 2019
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 12 Years and older

Eligibility

Inclusion Criteria:

1. Documented enrollment in the Usual Care Treatment Group of the HOPE-Duchenne trial and completion of trial follow-up through Month 12.

2. Willing and able to provide informed consent to participate in the trial if greater than or equal to (>=) 18 years of age, and assent with parental or guardian informed consent if less than (<) 18 years of age.

3. Adequate venous access for intravenous CAP-1002 infusions and routine blood collections in the judgement of the Investigator.

4. Assessed by the Investigator as willing and able to comply with the requirements of the trial.

Exclusion Criteria:

1. Left ventricular ejection fraction (LVEF) < 35 percent (%) within 6 months of screening.

2. Planned or likely major surgery in the next 6 months after planned first infusion.

3. Risk of near-term respiratory decompensation in the judgment of the investigator, or the need for initiation of non-invasive ventilator support as defined by serum bicarbonate >= 29 millimoles per liter (mmol/L) at screening.

4. History of non DMD-related chronic respiratory disease including, but not limited to, asthma, bronchitis, and tuberculosis.

5. Acute respiratory illness within 30 days prior to screening.

6. Known hypersensitivity to dimethyl sulfoxide (DMSO) or bovine products.

7. Treatment with investigational product <= 6 months prior to first infusion.

8. History, or current use, of drugs or alcohol that could impair ability to comply with participation in the trial.

9. Inability to comply with the investigational plan and follow-up visit schedule for any reason, in the judgment of the investigator.

Related Conditions & MeSH terms

• Cardiomyopathies
• Duchenne Muscular Dystrophy
• Muscular Dystrophies
• Muscular Dystrophy, Duchenne

Intervention

Biological:
• Allogeneic Cardiosphere-Derived Cells (CAP-1002)
Intravenous infusion delivery of Allogeneic Cardiosphere-Derived Cells (CAP-1002; 75 million CDCs)

Locations

Country	Name	City	State
United States	Cincinnati Children's Medical Center	Cincinnati	Ohio
United States	University of Florida	Gainesville	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Capricor Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants Experiencing Acute Respiratory Decompensation	Acute respiratory decompensation is defined as an unexplained rapid deterioration of the participant's condition with increasing shortness of breath requiring oxygen supplementation. Acute respiratory decompensation within 2 hours following investigational product (IP) administration will be reported.	2 hours post-dose on Day 1 and Month 3
Primary	Number of Participants With Hypersensitivity Reactions	Hypersensitivity reaction is defined as a clinical syndrome including, but not limited to, fever, leukocytosis, or rash with onset <= 2 hours post-infusion and lasting < 24 hours, in the absence of clinical signs of concomitant infection.	From Day 1 up to Month 6
Primary	All-cause Mortality	Number of deaths due to any cause will be reported.	From Day 1 up to Month 6
Primary	Number of Treatment-emergent Adverse Events (TEAEs) Related to Investigational Product or Administration and Serious Adverse Events (SAEs)	An adverse events (AEs) is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. TEAEs are defined as AEs occurring after the initiation of the IV catheter placement for the initial dose of IP. TEAEs related to investigational product or administration are reported for this outcome measure. A SAE is defined as an AE that results in any of the following outcomes: Death; life-threatening adverse event; Inpatient hospitalization or prolongation of existing hospitalization; persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions; congenital anomaly/birth defect.	From Day 1 up to Month 6
Primary	Number of Participants With Immune Sensitization Syndrome	Immune sensitization syndrome shall be defined as: (a) clinical signs and symptoms consistent with systemic inflammation (e.g., fever, leukocytosis, rash, or arthralgia) with onset >= 24 hours post infusion and the absence of clinical signs of concomitant infection, and (b) elevation of anti-human leukocyte antigen (HLA) antibodies against the donor cells (i.e., DSAs), detected <= 30 days following onset of syndrome, of (i) >= 2000 mean fluorescent intensity (MFI) if baseline MFI <= 1000, or (ii) >= 2 times baseline otherwise.	From Day 1 up to Month 6